ProfileGDS5678 / 1426844_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 91% 88% 88% 89% 88% 84% 89% 88% 88% 88% 86% 88% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.7150587
GSM967853U87-EV human glioblastoma xenograft - Control 27.5397591
GSM967854U87-EV human glioblastoma xenograft - Control 36.9588488
GSM967855U87-EV human glioblastoma xenograft - Control 47.0032588
GSM967856U87-EV human glioblastoma xenograft - Control 57.0320889
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.5256288
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.1161284
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.9318889
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.7443788
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.9311988
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.8420688
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.633586
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.8002188
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.1966290